Platinum-Resistant

Preliminary phase 2 results from the REJOICE-Ovarian01 trial show raludotatug deruxtecan (R-DXd) demonstrates clinically significant response in recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The study observed a 50.5% objective response rate across all doses. The Phase 3 portion will evaluate a 5.6 mg/kg dose of R-DXd against chemotherapy. R-DXd, a CDH6-directed antibody drug conjugate, is being jointly developed by Daiichi Sankyo and Merck, highlighting collaborative efforts in oncology drug development due to high unmet needs in late stage ovarian cancer.

The KEYNOTE-B96 Phase 3 trial demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with KEYTRUDA plus chemotherapy with or without bevacizumab in platinum-resistant recurrent ovarian cancer. The study showed PFS benefits in the overall population and OS benefits in patients with PD-L1 expressing tumors. The FDA has granted priority review to Merck’s sBLA for this combination, with a PDUFA date of Feb. 20, 2026, potentially changing treatment for this challenging disease.